Twisted Path Yields 1st Diabetes Drug Approved Since FDA Cardio Guidelines
Executive Summary
After FDA recently issued cardiovascular safety guidelines for diabetes medicines, many large drug makers returned to the clinic to revise their plans. But VeroScience, a small and relatively obscure company, won approval for its Cycloset medication to treat type 2 diabetes on the strength of Phase IIIb trial data that actually exceed FDA's standards
You may also be interested in...
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
There is one message that sponsors should take to heart from an FDA advisory committee's first pass at applying new cardiovascular outcomes standards to type 2 diabetes medicines: enroll sicker patients in pivotal trials
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs
FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.